Resumption of bone-modifying agents in relapsed multiple myeloma does not improve outcomes: A real-world analysis - PubMed
4 hours ago
- #multiple myeloma
- #relapsed refractory
- #bone-modifying agents
- Bone-modifying agents (BMAs) are established in frontline therapy for multiple myeloma but lack data supporting their use in relapsed settings.
- A retrospective analysis of 1112 relapsed/refractory multiple myeloma (RRMM) patients (2014-2023) showed no significant difference in progression-free survival (PFS) or overall survival (OS) between BMA-received and BMA-deferred groups at relapse.
- Median PFS was 10.1 months for BMA-deferred vs. 9.2 months for BMA-received (p=0.08). Median OS was 39.6 months for BMA-deferred vs. 51.5 months for BMA-received (p=0.10).
- The study suggests no clear benefit of BMA resumption in RRMM, advocating for personalized decision-making in future investigations.